Alnylam Pharmaceuticals NASDAQ ALNY
$149.45 -4.94 -3.31%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 27 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

18.77B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

19.08B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.

1.21
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.

125.61M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.

-21.92 %
Upcoming events Alnylam Pharmaceuticals All events
No upcoming events scheduled

Stock chart Alnylam Pharmaceuticals

Stock analysis Alnylam Pharmaceuticals

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
-42.64 14.25
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
-85.08 4.13
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
-97.56 9.88
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
-1.56 0.10
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
199.53 9.52

Price change Alnylam Pharmaceuticals per year

119.29$ 209.73$
Min Max

Summary analysis Alnylam Pharmaceuticals

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Alnylam Pharmaceuticals

Revenue and net income Alnylam Pharmaceuticals

All parameters
Stock news Alnylam Pharmaceuticals All news

Alnylam Pharmaceuticals shares fall after FDA advisers weigh in on heart-disease drug

Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA

Alnylam Pharmaceuticals Says FDA Panel Votes in Favor of Onpattro's sNDA

Alnylam Pharmaceuticals’ stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals Shares Jump 46% Premarket After Patisiran Trial Data

Alnylam Pharmaceuticals Shares Jump 46% Premarket After Patisiran Trial Data

Alnylam Pharmaceuticals Meets Primary Endpoint in Phase 3 Patisiran Study

Alnylam Pharmaceuticals Meets Primary Endpoint in Phase 3 Patisiran Study

Alnylam Pharmaceuticals Gets Positive CHMP Opinion for Vutrisiran

Alnylam Pharmaceuticals Gets Positive CHMP Opinion for Vutrisiran

Alnylam Pharmaceuticals Says FDA Extends Review Timeline for Vutrisiran

Alnylam Pharmaceuticals Says FDA Extends Review Timeline for Vutrisiran

Stellar Sales Growth Trend Makes Alnylam Pharmaceuticals Stock A Wise Bet

Alnylam Pharmaceuticals upgraded to buy from hold at UBS

На чем могут вырасти акции Alnylam Pharmaceuticals на 25%

About company Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; lumasiran for the treatment of advanced PH1 and recurrent renal stones; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Address:
675 West Kendall Street, Cambridge, MA, United States, 02142
Company name: Alnylam Pharmaceuticals
Issuer ticker: ALNY
ISIN: US02043Q1076
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 2004-05-28
Sector: Healthcare
Industry: Biotechnology
Site: https://www.alnylam.com

On which stock exchange are Alnylam Pharmaceuticals (ALNY) stocks traded?

Alnylam Pharmaceuticals (ALNY) stocks are traded on NASDAQ.

What is the ticker of Alnylam Pharmaceuticals stocks (ALNY)?

The stock ticker of Alnylam Pharmaceuticals’s stocks or in other words, the code is ALNY. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Alnylam Pharmaceuticals (ALNY) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Alnylam Pharmaceuticals (ALNY) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Alnylam Pharmaceuticals (ALNY) stocks traded?

Alnylam Pharmaceuticals (ALNY) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Alnylam Pharmaceuticals (ALNY) stocks today?

The current price of Alnylam Pharmaceuticals stocks on 29.03.2024 is 149.45 dollars. per share.

What is the dynamics of Alnylam Pharmaceuticals (ALNY) stocks from the beginning of the year?

Alnylam Pharmaceuticals (ALNY) quotes have increased by -23.33% from the beginning of the year up to 149.45 dollars. per 1 stocks.

How much did Alnylam Pharmaceuticals (ALNY) stocks increase in марте 2024?

This month Alnylam Pharmaceuticals (ALNY) quotes have increased by -2.07% to 149.45 dollars. per share.

How much are Alnylam Pharmaceuticals (ALNY) stocks worth?

Today, on October, 29.03.2024 Alnylam Pharmaceuticals’s (ALNY) stocks cost 149.45 dollars..

What is the market capitalization of Alnylam Pharmaceuticals (ALNY)?

Capitalization is the market value of Alnylam Pharmaceuticals (ALNY) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 29.03.2024, the market capitalization of Alnylam Pharmaceuticals (ALNY) is estimated at about 18772862850 dollars.